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The results of various studies performed in isolated hearts support
the notion that the potential range of changes in the value of the LC
in humans may be substantial, although in the recent paper by Bøtker
et al. (2), a reanalysis of data previously presented by Krivokapich et al.
(3), shows a less than twofold variation in the LC for various
physiologic changes (with values ranging between 0.45 and 0.85). In the
same report (2), estimations of the LC are made for two subjects in the
fasting state by means of the kinetics of F-18 FDG (the K1:K1 ratio).
Although this approach looks very promising, there are no reliable
data presented for the magnitude and range of values for the LC in
fasting humans.
Regarding the possible differences in the LC between the normal
and the transplanted heart, Doenst and Taegtmeyer suggest the
likelihood of an increase in the LC under conditions of increased
epinephrine or ischemia (unpublished observations). In the report by
Rechavia et al. (1), the possibility is raised that F-18 FDG uptake (and
therefore glucose utilization) may be increased because of a state of
chronic “demand ischemia.” This state is proposed in the context of a
substrate modifier, and in view of the modest increase in baseline
workload of the hearts in these patients (53%—with a proportionate
41% increase in flow relative to that in normal control subjects), it is
unrealistic to equate the status of the transplanted heart with full-
blown acute myocardial ischemia.
In their letter, Doenst and Taegtmeyer suggest that they have
evidence (unpublished observations) for an increase in the value of the
LC with epinephrine; yet (as an illustration of the variability in the
findings on this subject) they have themselves published data (4)
suggesting a constant relation between the kinetic behavior of F-18
FDG and glucose during the administration of epinephrine (i.e., a
constant value for the LC). Of equal importance, no indication for
changes in the value of the LC were noted in the same studies during
conditions of acute increase in workload. The additional finding that
F-18 FDG uptake was not increased during the administration of
insulin in those studies, contrary to the result of extensive experi-
ment in humans and documented in Bøtka et al. (2), highlights the
problem of extrapolating results from experimental animal models
to humans.
Taken together, these findings do not support the notion that a
significant difference in the value of the LC exists for the transplanted
heart. It is therefore not unreasonable to interpret the finding of a
threefold increase in F-18 FDG uptake in the heart transplant
recipients (1) as an increase in the rate of glucose utilization. However,
we do agree that there is a need for a simple and quantitative in vivo
assessment of the LC, such as that proposed by Bøtker et al. (2).
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QT Dispersion as a Marker of Risk in
Patients Awaiting Heart Transplantation?
We read with interest the report by Pinsky et al. (1) in a recent issue
of the Journal on a possible new application of QT dispersion from the
12-lead surface electrocardiogram (ECG). The question of whether
QT dispersion is a useful risk marker in patients with congestive heart
failure is still under dispute (1–7). Pinsky et al. (1) reported that QT
dispersion predicts death in patients awaiting list heart transplantation.
In their conclusion, the authors claim that the index “may help to
establish priority on a heart transplant waiting list.” Obviously, such
priority decisions may mean “life or death” in a given patient. The
validity and objectivity of a risk stratification test in this setting are
therefore of utmost importance.
Concerning the use of QT dispersion as a marker of arrhythmic
events or death in patients with congestive heart failure, the contrast-
ing results of available studies (1,4–7) indicate that the role and
methodology of QT dispersion is far from settled and remains sensitive
to methodologic discrepancies. We and others (2,8) have devoted
research efforts to the methodology of QT dispersion that have led to
entirely negative results for patients with congestive heart failure
(5–7). The report by Pinsky et al. (1) raises a number of important
methodologic questions.
1. QT dispersion cutoffs were determined post hoc, identifying a
high risk patient group of six patients with QT dispersion .140 ms.
Instead of calculating an odds ratio for such a small group, receiver
operator characteristic curves could have yielded more valid statistical
information. The average QT dispersion for both the event and
nonevent groups was found to be significantly higher than that in
published reports (4,6) and our own data (5,7). In our view, such
extreme QT dispersion values must raise the suspicion of measurement
errors.
2. An exact description of U wave identification was given; how-
ever, the incidence of U waves, which may have contributed to an
increased QT dispersion, is not mentioned in the results section.
3. The reader is unable to discern whether measurements were
taken by hand, by digitizing pad or with or without magnifying glasses.
Notably, only six measurable ECG leads were required. Apparently, a
4 3 3 lead ECG display was used, which does not give simultaneous
information for all 12 leads. This method is susceptible to errors
caused by transient changes in the RR interval and associated QT
intervals and may have increased the overall QT dispersion.
4. Patients with atrial fibrillation (n 5 13) were included in the
analysis. Again, changing RR and QT intervals between different beats
prohibits accurate determination of QT dispersion.
5. No information on the reproducibility of the measurements was
provided. Accurate measurement of QT intervals and QT dispersion,
which is prone to subjective operator errors, requires stringent controls
by comparing data from at least two independent blinded operators.
The discussion of the report, in our view, does not adequately
consider methodologic considerations or limitations. In conclusion, we
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believe that priority assessment in patients awaiting heart transplanta-
tion on the basis of QT dispersion measurements is premature.
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Reply
We appreciate the interest of Zabel and colleagues in our recent
report (1). We also agree that it is important to be clear regarding the
interpretation of our results. We would like to respond to their
comments.
1. The analysis of QT dispersion risk used two different measures of
dispersion: the maximal 2 minimal QT interval (QTDISP) and the
coefficient of variation of all QT intervals (QTCV). These variables
were highly significant (p 5 0.009 and p 5 0.001, respectively) when
analyzed as continuous variables without selection of a cutoff. The
dichotomization of patients on the basis of a cutoff for QTDISP of
140 ms and QTCV of 9% presented in our report was for illustrative
purposes only. The actual statistical model yields a continuum of risk
based on the value for QTDISP and QTCV. The significance of these
predictors remained after adjustment for other potential risk factors in
a multivariate analysis and after the removal of the 13 subjects with
atrial fibrillation. It can be seen in the original report that all analyses
consistently showed the utility of QT dispersion as a risk factor when
measured as described in the patient cohort under study (1).
Recent prospective studies (1,2) have demonstrated a significant
correlation between QT dispersion and mortality in patients with heart
failure, although some preliminary studies may suggest otherwise. It is
reasonable to assume that patients awaiting heart transplantation
represent a sicker subset of patients whose data may not be extrapo-
lated to patients with heart failure in general. We look forward to
reading the final published reports on the subject alluded to by Zabel
and colleagues (3,4).
2. The issue is raised that U waves may have contributed to an
increase in measured QT dispersion in the patients studied.
However, U waves were not included in the analysis (1) and therefore
did not contribute to increased QT dispersion in the original report.
3. In terms of electrocardiographic (ECG) analysis, the ECGs were
read by two independent observers blinded as to outcome, with the aid
of a magnifying lens, without a digitizing pad. The method for
obtaining ECGs was, as surmized, a standard 4 3 3 format. We used
this ECG format because it is currently the standard method for
obtaining ECGs and therefore most widely applicable with existing
equipment. Although transient changes in heart rate during the brief
period of acquisition could have affected QT dispersion, we doubt that
a sizable and systematic pattern would have occurred that would have
affected its measurement.
4. We considered the possibility that patients with atrial fibrillation
whose RR intervals can vary from beat to beat could have affected the
interpretation of our data. In fact, not only did we consider this
possibility, but we included specific data on this subject in the
published report (1). Although patients with atrial fibrillation were
included in most of the overall analyses, we did report specific data in
which the 13 patients with atrial fibrillation were excluded from
analysis (see Fig. 3 and the results and discussion sections). Indexes of
QT dispersion remained significant predictors of risk both before and
after the 13 subjects with atrial fibrillation were removed from the
analysis.
As ardent students of the scientific process, we hope that our work
serves as the springboard for additional studies in this area, so that we
can ultimately know how to best select patients who are still likely to
die while awaiting a donor heart.
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Echocardiography in Staphylococcus
aureus Bacteremia
Fowler et al. (1) investigated the diagnostic and prognostic usefulness
of transesophageal echocardiography (TEE) in patients with Staphy-
lococcus aureus bacteremia. The authors suggest that infective endo-
carditis is common in patients with S. aureus bacteremia and is
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